Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shot up 4.4% during trading on Monday. The stock traded as high as $10.46 and last traded at $10.1250. Approximately 1,057,048 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 5,111,479 shares. The stock had previously closed at $9.70.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on NTLA. Barclays started coverage on shares of Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price objective for the company. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research report on Friday. Wedbush lifted their price target on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $21.44.
Read Our Latest Stock Analysis on Intellia Therapeutics
Intellia Therapeutics Price Performance
The business has a fifty day simple moving average of $11.92 and a two-hundred day simple moving average of $12.96. The company has a market cap of $1.40 billion, a PE ratio of -2.98 and a beta of 1.83.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 64.74% and a negative net margin of 805.75%. The company had revenue of $7.16 million during the quarter, compared to the consensus estimate of $9.74 million. During the same period in the previous year, the firm posted ($0.92) earnings per share. The company’s revenue was down 47.8% on a year-over-year basis. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -3.28 EPS for the current year.
Insider Buying and Selling
In other news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares in the company, valued at approximately $13,645,387.36. This trade represents a 0.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.50% of the company’s stock.
Hedge Funds Weigh In On Intellia Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers increased its stake in shares of Intellia Therapeutics by 13.1% in the third quarter. Cetera Investment Advisers now owns 75,679 shares of the company’s stock worth $913,000 after acquiring an additional 8,737 shares during the period. Entropy Technologies LP purchased a new position in shares of Intellia Therapeutics during the third quarter worth $1,448,000. Pathstone Holdings LLC lifted its position in Intellia Therapeutics by 6.9% during the third quarter. Pathstone Holdings LLC now owns 41,468 shares of the company’s stock valued at $500,000 after purchasing an additional 2,686 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Intellia Therapeutics by 225.7% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the company’s stock valued at $25,000 after purchasing an additional 1,447 shares during the period. Finally, Insigneo Advisory Services LLC lifted its position in Intellia Therapeutics by 175.0% during the third quarter. Insigneo Advisory Services LLC now owns 33,000 shares of the company’s stock valued at $398,000 after purchasing an additional 21,000 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.
See Also
- Five stocks we like better than Intellia Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
